(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a kidney cancer session and a presentation by Dr. Jodi Maranchie discussing targeting HIF-2alpha in von-Hippel Lindau (VHL) patients. Dr. Maranchie starts by noting that the manifestations and penetrance of VHL lesions are highly variable based on anatomic location: